miophthalmology products

Miniject is iSTAR Medical’s innovative microinvasive glaucoma surgery
(MIGS) device for patients with primary open-angle glaucoma. Miniject combines the distinctive porous structure of its proprietary Star material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis, and subsequent complications.

The Hydrus Microstent is an innovative canal-based, minimally invasive glaucoma surgery (MIGS) device for patients with mild-to-moderate primary open-angle glaucoma. This device is the only MIGS implant to span approximately 90° of Schlemm’s canal, ensuring access to collector channels in the nasal region.1-3 The first MIGS device to precisely dilate and scaffold Schlemm’s canal, it gently expands the cross sectional area without obstructing outflow access to collector channel ostia.1-3 The Hydrus Microstent bypasses the trabecular meshwork to restore flow of aqueous from the anterior chamber through the inlet of the microstent into Schlemm’s canal.1

The Spectralis with glaucoma module premium edition combines a patented anatomic positioning system (APS) that creates an anatomic map of each patient’s eye using two fixed landmarks: the centre of the fovea, and the centre of Bruch’s membrane opening. With APS, all glaucoma protocols are automatically oriented according to the patient’s individual anatomy. Combined with the clinical benefits of TruTrack active eye tracking and AutoRescan, allowing reproducibility to 1 μm, this allows for potentially earlier diagnosis, even in challenging cases with very small changes over time. This precise examination ensures accurate comparisons with reference data, allowing for a highly sensitive assessment of change across the optic nerve head, the retinal nerve
fibre layer, and macular ganglion cell layer.

Melbourne Rapid Fields (MRF) rapid online perimetry is a groundbreaking
device-independent perimeter now used by over 280 clinics globally. Registered by the Therapeutic Goods Administration and CE Marked, it allows patients to conduct visual field tests in-clinic and at home. At this year's Asia Pacific Glaucoma Congress in Manila, Associate Professor George Kong presented innovative study results on home monitoring for glaucoma using MRF Rapid. The findings revealed a high correlation between home-based MRF and clinic-based Humphrey field analyser tests, with a strong test-retest reliability (ICC of 0.97) for home tests. This advancement signifies a potential transformation in glaucoma care and research, making it more accessible and effective for patients worldwide.

The patented micropulse P3 and G-probe devices are used to deliver laser energy for the treatment of glaucoma. The system enables a versatile, non-incisional procedure with multiple safety benefits, including minimal to zero inflammation post-op. Patient downtime is reduced significantly and the procedure is repeatable and predictable. Proprietary micropulse technology finely controls thermal elevation by ‘chopping’ a continuous-wave laser beam into a train of repetitive short pulses. This allows tissue to cool between pulses, reducing thermal build-up and preventing visible tissue damage. An illuminated G-Probe is now available. The Cyclo G6 system is distributed exclusively in Australia by Optimed.

The iStent infinite includes three heparin-coated titanium stents preloaded into an auto-injection system that allows the surgeon to inject stents across a span of up to approximately six clock hours around Schlemm’s canal, the eye’s primary drainage channel. Once in place, the stents are designed to lower intraocular pressure by restoring the natural, physiological outflow of aqueous humor. The iStent infinite has a similar mechanism of action to Glaukos’ two-stent iStent inject W
trabecular micro-bypass system.